BARONCIANI, LUCIANO
BARONCIANI, LUCIANO
DIPARTIMENTO DI MEDICINA INTERNA (attivo dal 01/01/1998 al 27/04/2012)
The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients
2022 M.T. Pagliari, L. Baronciani, C. Cordiglieri, P. Colpani, G. Cozzi, S.M. Siboni, F. Peyvandi
Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease : REPLY from original authors Biguzzi et al
2021 E. Biguzzi, S.M. Siboni, S. le Cessie, L. Baronciani, F.R. Rosendaal, A. van Hylckama Vlieg, F. Peyvandi
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
2021 L. Baronciani, I. Peake, R. Schneppenheim, A. Goodeve, M. Ahmadinejad, Z. Badiee, M.-. Baghaipour, O. Benitez, I. Bodo, U. Budde, A. Cairo, G. Castaman, P. Eshghi, J. Goudemand, W. Hassenpflug, H. Hoorfar, M. Karimi, B. Keikhaei, R. Lassila, F.W.G. Leebeek, M.F.L. Fernandez, P.M. Mannucci, R. Marino, N. Niksic, F. Oyen, C. Santoro, A. Tiede, G. Toogeh, A. Tosetto, M. Trossaert, E.M.K. Zetterberg, J. Eikenboom, A.B. Federici, F. Peyvandi
Pulmonary tumour thrombotic microangiopathy in a young man: clinical and immunohistochemical characterisation of a rare complication of gastric signet-ring cell carcinoma
2021 R. Rossio, E. Pagliaro, A. Artoni, L. Baronciani, R. Russo, M.C. Mocellin, G. Lopez, F. Peyvandi
Bleeding symptoms in patients diagnosed as type 3 Von Willebrand Disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study
2020 A. Tosetto, Z. Badiee, M. Baghaipour, L. Baronciani, J. Battle, E. Berntorp, I. Bodó, U. Budde, G. Castaman, J.C.J. Eikenboom, P. Eshghi, C. Ettorre, A. Goodeve, J. Goudemand, H. Charles Richard Morris, H. Hoorfar, M. Karimi, B. Keikhaei, R. Lassila, F.W.G. Leebeek, M.F. Lopez Fernandez, P.M. Mannucci, M.G. Mazzucconi, M. Morfini, J. Oldenburg, I. Peake, R. Parra Lòpez, F. Peyvandi, R. Schneppenheim, A. Tiede, G. Toogeh, M. Trossaert, O. Zekavat, E.M.K. Zetterberg, A.B. Federici
Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers
2020 A. Szederjesi, L. Baronciani, U. Budde, G. Castaman, P. Colpani, A.S. Lawrie, Y. Liu, R. Montgomery, F. Peyvandi, R. Schneppenheim, J. Patzke, I. Bodó
Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease
2020 F. Stufano, L. Baronciani, P. Bucciarelli, M. Boscarino, P. Colpani, M.T. Pagliari, F. Peyvandi
The ADAMTS13-von Willebrand factor axis in COVID-19 patients
2020 I. Mancini, L. Baronciani, A. Artoni, P. Colpani, M. Biganzoli, G. Cozzi, C. Novembrino, M. Boscolo Anzoletti, V. De Zan, M.T. Pagliari, R. Gualtierotti, S. Aliberti, M. Panigada, G. Grasselli, F. Blasi, F. Peyvandi
How we make an accurate diagnosis of von Willebrand disease
2019 L. Baronciani, F. Peyvandi
Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome
2019 F. Stufano, M. Boscarino, P. Bucciarelli, L. Baronciani, A. Maino, G. Cozzi, F. Peyvandi
Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus
2019 F. Stufano, L. Baronciani, E. Biguzzi, G. Cozzi, P. Colpani, M. Chisini, F. Peyvandi
An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study
2018 A. Szederjesi, L. Baronciani, U. Budde, G. Castaman, A.S. Lawrie, Y. Liu, R. Montgomery, F. Payvandi, R. Schneppenheim, A. Várkonyi, J. Patzke, I. Bodó
Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation
2018 M.T. Pagliari, L. Baronciani, F. Stufano, P. Colpani, S.M. Siboni, F. Payvandi
A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method
2018 F. Stufano, L. Baronciani, D. Mane-Padros, G. Cozzi, S. Faraudo, F. Peyvandi
Molecular diagnosis of von Willebrand disease
2017 L. Baronciani, A. Goodeve, F. Peyvandi
von Willebrand disease type 1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergistically determine a 2M phenotype in four Italian patients
2016 M.T. Pagliari, L. Baronciani, F. Stufano, I. Garcia-Oya, G. Cozzi, F. Franchi, F. Peyvandi
Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels
2015 P. Bucciarelli, S.M. Siboni, F. Stufano, E. Biguzzi, M.T. Canciani, L. Baronciani, M.T. Pagliari, S. La Marca, C. Mistretta, F.R. Rosendaal, F. Peyvandi
A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand Syndrome
2014 F. Franchi, E. Biguzzi, F. Stufano, S.M. Siboni, L. Baronciani, F. Peyvandi
A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen
2013 F. Stufano, A.S. Lawrie, S. La Marca, P.E.C. Berbenni, L. Baronciani, F. Peyvandi
A synonymous (c.3390C>T) or a splice-site (c.3380-2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A/IIE)
2013 M.T. Pagliari, L. Baronciani, I. Garcìa Oya, M. Solimando, S. La Marca, G. Cozzi, F. Stufano, M.T. Canciani, F. Peyvandi